GLP-1 Drugs and Heart Disease
2 articles in this topic.
GLP-1 Drugs and Heart Disease
The SELECT Trial: Semaglutide Cut Heart Risk 20%
The SELECT trial proved semaglutide 2.4 mg reduced heart attacks, strokes, and cardiovascular death by 20% in 17,604 patients with obesity but no diabetes.
13 min read|Mar 25, 2026
GLP-1 Drugs and Heart Disease
SUMMIT Trial: Tirzepatide Cut Heart Failure Risk 38%
The SUMMIT trial showed tirzepatide reduced CV death or worsening heart failure by 38% in 731 patients with HFpEF and obesity. Full results breakdown.
13 min read|Mar 25, 2026